甲状腺微小乳头状癌CK19和CD56的表达及与疾病进展的关系

Expression of thyroid papillary microcarcinoma CK19 and CD56 and its relationship with disease progression

目的探讨甲状腺微小乳头状癌（PMC）CK19和CD56的表达及与疾病进展的关系。方法选择2012年1月-2015年1月收治的120例PMC患者作为观察组,另选择同期收治的120例甲状腺乳头状增生患者作为对照组,比较两组的临床病理特征（病灶直径、肿瘤分期、组织学分化、淋巴结转移）和CK19及CD56免疫组化检测结果。结果观察组CK19和CD56的阳性表达率分别为83.3%和6.7%,对照组分别为5.0%和60.0%,两组比较有显著差异（P〈0.01）。在观察组的癌组织中,临床分期越高、分化程度越低和有淋巴结转移者的CK19的阳性表达率越高,CD56的阳性表达率越低（P〈0.05）。结论CK19和CD56的免疫组化检测能有效鉴别微小乳头状癌与乳头状增生,且CK19和CD56的表达水平与PMC的临床病理特征有一定的相关性。

Objective To investigate the expression of thyroid papillary microcarcinoma（PMC） CK19 and CD56 and its relationship with disease progression. Methods 120 PMC patients hospitalized between January 2012 and January 2015 were selected as observation group. Another 120 patients with thyroid papillary hyperplasia hospitalized at the same time were chosen as control group. Comparison was made in the clinical pathological features（focus diameter, tumor staging, histological differentiation,and lymph node metastasis） and immunohistochemical results of CK19 and CD56 between the two groups. Results The positive expression rates of CK19 and CD56 in the observation group were 83.3% and 6.7%, and those of the control group were 5.0% and60.0%, respectively. The differences were significant between the two groups（P〈 0.01）. In the observation group, the positive rates of CK19 were higher, and that of CD56 were lower in tumor tissues of higher clinical staging and lower differentiation degrees and in patients with lymph node metastasis（P〈 0.05）. Conclusion CK19 and CD56 immunohistochemical detection can effectively identify the papillary thyroid cancer and papillary thyroid hyperplasia. The expression levels of CK19 and CD56 have certain correlation with the clinical pathological features.